Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide CV Outcomes in Type 2 Diabetes (REWIND)
NCT01394952Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2011
- Primary completion
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 25
01
Overview
A Phase 3 trial of dulaglutide biosimilar 14028 injection in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Jul 2011; status: completed.
02
Drugs
dulaglutide biosimilar 14028 injection
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01394952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01394952.